Be part of the knowledge.™

Gastroenterology and Hepatology

189

LikeLikedUnlike

46-60 of 92

Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
- James M. Cleary, MD, PhD
0.50 program credits
MinuteCE®
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  
- James M. Cleary, MD, PhD
0.50 credits 4 episodes
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
- James M. Cleary, MD, PhD
0.50 program credits
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
MinuteCE®
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
- Pam R. Taub, MD, FACC, FASPC
- Kausik Ray, MBChB, MD, MPhil
1.00 program credits
SHTG: Defining the Unmet Clinical Need
MinuteCE®
SHTG: Defining the Unmet Clinical Need
- Pam R. Taub, MD, FACC, FASPC
- Kausik Ray, MBChB, MD, MPhil
1.00 program credits
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
MinuteCE®
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
- Børge G. Nordestgaard, MD, DMSc
- Kausik Ray, MBChB, MD, MPhil
1.00 program credits
advertisement
Latest Clinical Trial Outcomes and Breakthroughs for FCS
MinuteCE®
Latest Clinical Trial Outcomes and Breakthroughs for FCS
- Daniel Gaudet, MD, PhD
- Pam R. Taub, MD, FACC, FASPC
1.00 program credits
APOC3 Inhibition: A Novel Approach to Lowering TGs
MinuteCE®
APOC3 Inhibition: A Novel Approach to Lowering TGs
- Børge G. Nordestgaard, MD, DMSc
- Kausik Ray, MBChB, MD, MPhil
1.00 program credits
FCS: Enhancing the Diagnosis
MinuteCE®
FCS: Enhancing the Diagnosis
- Daniel Gaudet, MD, PhD
1.00 program credits
MinuteCE®
APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
- Daniel Gaudet, MD, PhD
- Børge G. Nordestgaard, MD, DMSc
- Pam R. Taub, MD, FACC, FASPC
- Kausik Ray, MBChB, MD, MPhil
1.00 credits 9 episodes
Remnant Cholesterol: The Missing Link in ASCVD risk
MinuteCE®
Remnant Cholesterol: The Missing Link in ASCVD risk
- Børge G. Nordestgaard, MD, DMSc
- Kausik Ray, MBChB, MD, MPhil
1.00 program credits
SHTG: Decoding the Latest Clinical Trial Outcomes
MinuteCE®
SHTG: Decoding the Latest Clinical Trial Outcomes
- Pam R. Taub, MD, FACC, FASPC
- Kausik Ray, MBChB, MD, MPhil
1.00 program credits
advertisement
The Road Ahead: What's on the Horizon for FCS and SHTG Management
MinuteCE®
The Road Ahead: What's on the Horizon for FCS and SHTG Management
- Pam R. Taub, MD, FACC, FASPC
- Prof. Kausik Ray
1.00 program credits
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
- Harry Yoon, MD
- Jaffer Ajani, MD
0.75 program credits
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
- Harry Yoon, MD
- Jaffer Ajani, MD
0.75 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended